Compare GSK plc (GSK) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Transocean Ltd — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Transocean Ltd trades at $5.55 (market cap $6.19B). The key difference: GSK plc is far larger — about 14.8× Transocean Ltd's market cap, and GSK plc pays a 3.9% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Transocean Ltd for 18 Days on average.
| GSK | RIG | |
|---|---|---|
Market Cap | $91.88B | $6.19B |
Volume | 7,730,529 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $61.18 | $7.58 |
52-Week Low | $43.24 | $3.08 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $111.88B | $10.80B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Transocean (RIG) trades at $5.595, up 3.8% with bullish technical signals despite mixed earnings. The company shows strong revenue growth to $4.1B in 2026 but remains unprofitable with a -40.24% net margin. Recent $80M and $300M contract wins boost backlog, while the $5.8B Valaris acquisition advances after DOJ approval. Cash flow improved with $995M operating cash in 2026, supporting deleveraging efforts amid high debt levels.
RIG offers speculative upside through offshore cycle leverage and contract growth, but high debt and persistent losses pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about cash flow improvement versus concerns over profitability and execution risks from major acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
